Vanguard Group Inc Immunity Bio, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 16,902,516 shares of IBRX stock, worth $75.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,902,516
Previous 13,831,796
22.2%
Holding current value
$75.9 Million
Previous $87.4 Million
28.26%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IBRX
# of Institutions
202Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Black Rock Inc. New York, NY11.4MShares$51.3 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$38.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$17.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$10.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.07MShares$9.29 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.8B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...